| Literature DB >> 34021159 |
Michael K McCracken1, Caitlin H Kuklis1, Chandrika B Kannadka1, David A Barvir1, Mark A Sanborn1, Adam T Waickman1, Hayden C Siegfried1, Kaitlin A Victor1, Kristin L Hatch1, Rafael De La Barrera2, Shannon D Walls1, Wiriya Rutvisuttinunt1, Jeffrey R Currier1, Heather Friberg1, Richard G Jarman1, Gregory D Gromowski3.
Abstract
Antibody-dependent enhancement (ADE) is suspected to influence dengue virus (DENV) infection, but the role ADE plays in vaccination strategies incorporating live attenuated virus components is less clear. Using a heterologous prime-boost strategy in rhesus macaques, we examine the effect of priming with DENV purified inactivated vaccines (PIVs) on a tetravalent live attenuated vaccine (LAV). Sera exhibited low-level neutralizing antibodies (NAb) post PIV priming, yet moderate to high in vitro ADE activity. Following LAV administration, the PIV primed groups exhibited DENV-2 LAV peak viremias up to 1,176-fold higher than the mock primed group, and peak viremia correlated with in vitro ADE. Furthermore, PIV primed groups had more balanced and higher DENV-1-4 NAb seroconversion and titers than the mock primed group following LAV administration. These results have implications for the development of effective DENV vaccine prime-boost strategies and for our understanding of the role played by ADE in modulating DENV replication.Entities:
Year: 2021 PMID： 34021159 DOI： 10.1038/s41541-021-00339-y
Source DB: PubMed Journal: NPJ Vaccines ISSN： 2059-0105 Impact factor: 7.344